These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 45088)

  • 41. [Subinhibitory activity of cefaclor and cephalexin (author's transl)].
    Shah PM; Staszewski S
    Infection; 1979; 7 Suppl 6():543-6. PubMed ID: 399246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefaclor: in vitro spectrum of activity and beta-lactamase stability.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1978 Apr; 13(4):584-8. PubMed ID: 666290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.
    Wiseman LR; Benfield P
    Drugs; 1993 Feb; 45(2):295-317. PubMed ID: 7681376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fundamental and clinical studies of S 6472 (sustained release preparation of cefaclor) in the pediatric field].
    Sugita M; Toyonaga Y; Nakamura H; Kurosu Y; Hori M
    Jpn J Antibiot; 1985 Sep; 38(9):2444-52. PubMed ID: 3908736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.
    Wise R; Andrews JM; Thornber D
    J Antimicrob Chemother; 1991 Aug; 28(2):239-48. PubMed ID: 1778855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.
    Jones RN; Barry AL
    J Clin Microbiol; 1988 Apr; 26(4):770-3. PubMed ID: 3259247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3-Deacetoxy-7-(alpha-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100), a new semisynthetic cephalosporin. I. Comparative in vitro antibacterial activities of SCE-100 and cephalexin (CEX).
    Yamazaki T; Tsuchiya K
    J Antibiot (Tokyo); 1976 May; 29(5):559-65. PubMed ID: 956045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
    Hiraoka M; Masuyoshi S; Tomatsu K; Inoue M; Mitsuhashi S
    Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo evaluation of MDL 19,592, an oral cephalosporin.
    Erickson RC; Baumann RJ; Gibson CB; Hoffman PF
    J Antibiot (Tokyo); 1983 Oct; 36(10):1345-56. PubMed ID: 6605961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparison of the activity of cefaclor with amoxicillin, erythromycin and doxycycline in an in vitro model].
    Wiedemann B
    Arzneimittelforschung; 1983; 33(9):1232-5. PubMed ID: 6357205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis.
    Sydnor A; Gwaltney JM; Cocchetto DM; Scheld WM
    Arch Otolaryngol Head Neck Surg; 1989 Dec; 115(12):1430-3. PubMed ID: 2510772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antibacterial activity of cefotaxim in comparison with seven cephalosporins].
    Braveny I; Dickert H; Machka K
    Infection; 1979; 7(5):231-6. PubMed ID: 389804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and in vivo antibacterial activity of KT3777, a new orally active carbacephem.
    Sato K; Okachi R; Matsukuma I; Mochida K; Hirata T
    J Antibiot (Tokyo); 1989 Dec; 42(12):1844-53. PubMed ID: 2621166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PK-PD modelling of the effect of cefaclor on four different bacterial strains.
    de la Peña A; Gräbe A; Rand KH; Rehak E; Gross J; Thyroff-Friesinger U; Müller M; Derendorf H
    Int J Antimicrob Agents; 2004 Mar; 23(3):218-25. PubMed ID: 15164961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of action of the new orally active cephalosporin FK027.
    Shigi Y; Matsumoto Y; Kaizu M; Fujishita Y; Kojo H
    J Antibiot (Tokyo); 1984 Jul; 37(7):790-6. PubMed ID: 6381449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.
    Ahmed A; Hafiz S; Rafiq M; Tariq N; Abdulla EM; Hussain S; Azim R; Siddiqui SJ; Awan A; Khan KZ; Fareed A
    J Pak Med Assoc; 2002 Jan; 52(1):7-11. PubMed ID: 11963587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine.
    Silver MS; Counts GW; Zeleznik D; Turck M
    Antimicrob Agents Chemother; 1977 Nov; 12(5):591-6. PubMed ID: 921255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibacterial activity and beta-lactamase stability of MDL 19,592, an oral cephalosporin.
    Yu KW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(5):441-3. PubMed ID: 2515027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.